- Home
- VTGN vs GUTS Comparison
VTGN vs GUTS Comparison
Compare VTGN & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- GUTS
- Stock Information
- Founded
- VTGN 1998
- GUTS 2010
- Country
- VTGN United States
- GUTS United States
- Employees
- VTGN N/A
- GUTS N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- GUTS
- Sector
- VTGN Health Care
- GUTS
- Exchange
- VTGN Nasdaq
- GUTS NYSE
- Market Cap
- VTGN 62.9M
- GUTS 58.8M
- IPO Year
- VTGN N/A
- GUTS 2024
- Fundamental
- Price
- VTGN $2.26
- GUTS $1.54
- Analyst Decision
- VTGN
- GUTS Buy
- Analyst Count
- VTGN 0
- GUTS 1
- Target Price
- VTGN N/A
- GUTS $10.00
- AVG Volume (30 Days)
- VTGN 96.9K
- GUTS 253.6K
- Earning Date
- VTGN 06-10-2025
- GUTS 05-13-2025
- Dividend Yield
- VTGN N/A
- GUTS N/A
- EPS Growth
- VTGN N/A
- GUTS N/A
- EPS
- VTGN N/A
- GUTS N/A
- Revenue
- VTGN $698,000.00
- GUTS $60,000.00
- Revenue This Year
- VTGN N/A
- GUTS N/A
- Revenue Next Year
- VTGN N/A
- GUTS N/A
- P/E Ratio
- VTGN N/A
- GUTS N/A
- Revenue Growth
- VTGN N/A
- GUTS N/A
- 52 Week Low
- VTGN $1.90
- GUTS $0.87
- 52 Week High
- VTGN $4.75
- GUTS $7.89
- Technical
- Relative Strength Index (RSI)
- VTGN 47.92
- GUTS 55.35
- Support Level
- VTGN $2.25
- GUTS $1.47
- Resistance Level
- VTGN $2.38
- GUTS $1.79
- Average True Range (ATR)
- VTGN 0.12
- GUTS 0.16
- MACD
- VTGN 0.02
- GUTS 0.03
- Stochastic Oscillator
- VTGN 45.71
- GUTS 56.56
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.